Author: Editor-In-Chief
To commemorate the 800th anniversary of St. Francis of Assisi’s death, the remains of St. Francis have been exhibited to the public for the first time. On Saturday morning, the saint’s skeleton was exhumed from a sarcophagus in the crypt of the Basilica of St. Francis of Assisi in the central Italian town of Assisi. The bones were then laid out on a table in the crypt before being transferred to the lower church of the basilica. Later that day, about 300 monks attended a Solemn Vespers celebration in the lower church, according to a statement from the cathedral. The…
Rory McIlroy said he was happy with his positive progress at the Genesis Invitational, despite falling just short after Sunday’s surge.Jacob Bridgman fought off attacks from McIlroy and Kurt Kitayama to win his first PGA Tour title with a one-shot victory at 18 under par at Riviera Country Club. Although McIlroy didn’t get his first win of the season, he insisted the week was an encouraging step towards the Arnold Palmer Invitational and The Players Championship. “If you look at my play last week (at the AT&T Pebble Beach Pro-Am), I definitely had some big numbers, making birdies, but I…
The last five days to save up to $680 on TechCrunch Disrupt 2026 tickets are officially over. These yearly lowest rates expire on February 27th at 11:59 PM PT. If you’re planning your 2026 technology events calendar, now is not the time to wait. Register now to secure savings before prices go up. What to expect at Disrupt 2026 Each year, Disrupt brings together more than 10,000 founders, technology leaders, and venture capitalists to San Francisco’s Moscone West. From October 13th to 15th, you’ll gain valuable lessons and curated networking opportunities designed to elevate your startup’s trajectory, accelerate your career,…
So much has happened this year, but the market suggests not much has changed. War warnings, policy shifts, the hunt for AI victims, at least one private company worth an estimated $1 trillion looming on the public market, and much more. But overall, the portfolio and economic context remain largely unchanged. The S&P 500 index is loaded with top-quality stocks, which explains its extreme stagnation. The index exceeded the 6,900 level in more than 40% of all trading sessions over the past two months. The first time this level was touched was on October 28th. By this time in February,…
AI robots will outnumber the workforce within decades as more companies hire AI agents and continue to squeeze costs, a former Citi executive warned on Monday. Rob Garlick, former head of innovation, technology and the future of work at Citi Global Insights, told CNBC’s “Squawk Box Europe” that human workers will be ignored as leaders continue to prioritize profitability. “We have a leadership system that focuses on profitability, both economically and business-wise,” Garlick said in a conversation with CNBC’s Steve Sedgwick and Ben Boulos. “Combining profitability with technological advances will usher in the greatest trade in history. Essentially, artificial intelligence…
McLaren team boss Andrea Stella believes Ferrari and Mercedes are “a step ahead” following F1’s final pre-season test for 2026 last week.Ferrari’s Charles Leclerc completed an impressive final day, topping the timesheets by more than eight tenths of a second over Lando Norris and running a strong race simulation in the heat of the day. Despite ticking all the test boxes ahead of the season-opening Australian Grand Prix from March 6-8, which will be broadcast live on Sky Sports F1, Stella believes McLaren are not “that far” behind the top two teams. Asked about the pecking order, he said: “It’s…
Check out the companies making headlines before the bell. ARCELUX — Biotech stocks soared 78% after Gilead Sciences announced Monday that it has agreed to acquire Arcelx for $7.8 billion, offering $115 per share in cash and a $5 per share contingent value right at closing. Arcellx focuses on immunotherapy for patients with cancer and other difficult diseases. The transaction is expected to close in the second quarter. Novo Nordisk , Eli Lilly — Novo Nordisk fell 14% after its weight-loss drug Kaglisema failed to compete with Eli Lilly’s drug in a recent trial. Eli Lilly shares rose nearly 3%.…
Every time Michelle Harris leaves her Montmartre apartment and heads around the corner to the small courtyard, she has no idea how long her errand will take. “Especially in the summer, there are times when I’m gone for two minutes or even an hour,” Harris, who is from Virginia, told CNN Travel, explaining that it’s nearly impossible to say “hello” to neighbors when they stop you. “French people are very charming… if they stop you, they will talk to you. They are interested in what you are doing, even taking out the trash.” Harris, who moved permanently to Paris in…
“Can I play with you every week?”This chant is often heard inside soccer stadiums, for example, when a team immediately wins 4-0 against their opponent. It’s also one of the matches that England cricket supporters may be overjoying, as the England team continues their momentum by crushing Sri Lanka in the T20s, despite losing the World Cup victory at Palekele. England have now won their last 12 T20s against their opponents, including a convincing 3-0 victory in the pre-World Cup bilateral series, also played at Palekele. Sri Lanka have not beaten England in this format since May 2014 at Kier…
novo nordisk Shares fell 15% on Monday after the company announced it did not meet a key goal of showing its next-generation weight loss drug is as good as other products. Eli Lilly”rival drug.Novo said in a statement Monday morning that the drug, Kaglisema, failed to meet its primary endpoint of demonstrating non-inferiority in weight loss after 84 weeks compared to Eli Lilly’s rival drug, tirzepatide. Tirzepatide is the active ingredient in Lilly’s blockbuster drugs Munjaro and Zepbound, which have overtaken Novo Nordisk’s semaglutide, sold by prescription in the U.S. as Ozempic and Wigovy. Novo’s Copenhagen-listed shares last fell 15%…